Article
[Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
Zhonghua yi xue za zhi - 25 Apr 2023
Wang C, Li Y, Guan Y, Yang S J, Yin J C, Zhang C F, Guo Q S, Shi W N
Abstract excerpt
Objective: To investigate the efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer (NSCLC) who failed epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. Methods: A retrospective analysis was made on the clinical data of 60 NSCLC patients who were treated with immunotherapy combined with chemotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.